Search
Advertisement
neetu chandra sharma
Neetu Chandra Sharma

Neetu Chandra Sharma

TVTN

neetu.chandra@aajtak.com

Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With over two decades of experience in top Indian newsrooms—including Mint, Hindustan Times, the India Today Group, ...

SHOW MORE...

Follow Neetu Chandra Sharma on:

Dr. Upasana Arora, Managing Director, Yashoda Group of Hospitals

Yashoda Medicity targets break-even in 3 years, plans 600 more beds

by Neetu Chandra Sharma |Sep 15, 2026

MD Upasana Arora says the group is pursuing brownfield hospital acquisitions as Medicity scales up from 625 beds.

Chaitanya Sarawate, President & CEO of GE HealthCare, said the firm is also open to acquisitions that can expand its engineering capabilities, manufacturing capacity or differentiation in the market.

GE HealthCare targets 2X+ exports from India by 2030

by Neetu Chandra Sharma |Sep 14, 2026

Company wants 75% of India revenue from locally designed and manufactured products as it deploys the bulk of its ₹8,000-crore investment.

Novartis ₹1,250 Crore Acquisition: Why Is The Pharma Giant Betting Big On Minipress XL?

Novartis ₹1,250 Crore Acquisition: Why Is The Pharma Giant Betting Big On Minipress XL?

by Sakshi Batra |Sep 9, 2026

Novartis is making a strategic move in India’s fast-growing cardiology segment with the acquisition of Minipress XL for around ₹1,250 crore. The brand generated ₹228.6 crore in revenue over the last 1...

Indegene’s Growth Story: Global Expansion, AI & The Future Of Healthcare Tech

Indegene’s Growth Story: Global Expansion, AI & The Future Of Healthcare Tech

by Shailendra Bhatnagar |Sep 8, 2026

Indegene is at an interesting point in its growth journey as healthcare, technology and artificial intelligence reshape the global life sciences industry. In this edition of Business Outlook, Manish G...

Mounjaro Sales Surge 502%: Why GLP-1 Drugs Are Taking Over India’s Pharma Market

Mounjaro Sales Surge 502%: Why GLP-1 Drugs Are Taking Over India’s Pharma Market

by Sakshi Batra |Sep 7, 2026

India’s pharma market is witnessing a major shift as diabetes and weight-management therapies gain rapid traction. PharmaTrac’s August 2026 data shows the overall pharma market grew 10.4%, while the a...

Metropolis Healthcare Bets On AI, Expansion And Deeper Penetration

Metropolis Healthcare Bets On AI, Expansion And Deeper Penetration

by Neetu Chandra Sharma |Sep 7, 2026

Metropolis Healthcare has outlined a three-year growth strategy focused on accelerating organic growth through technology-led transformation, network expansion and deeper market penetration. The diagn...

India, she said, offered a particularly compelling example because of the scale at which these approaches were being deployed.

NHS England chair sees India becoming a global exemplar in healthcare 

by Neetu Chandra Sharma |Sep 3, 2026

Dash said India’s approach to technology in healthcare was particularly interesting because of the way it can be used to “democratise access to healthcare”, Dr Penny Dash, Chair of NHS England, said.

The improvement in profitability was significantly greater than revenue growth.

Pharma API, CRAMS firms see sharp profit acceleration in Q1 FY27

by Neetu Chandra Sharma |Sep 3, 2026

Median PAT growth rises to 47% from 8% in March quarter, as CDMO projects, capacity additions and new products start contributing to earnings.

Around 70% of Rusan’s turnover comes from narcotic and psychotropic products, according to the company.

Rusan Pharma targets ₹20,000-25,000 crore addiction treatment market, to invest ₹200 crore in Kandla

by Neetu Chandra Sharma |Sep 3, 2026

Company expects addiction treatment and critical pain management to contribute to growth as it expands manufacturing capacity and overseas business.

Gland Pharma, Caplin Point, Nephrocare: These 3 Pharma Stocks See Strong Growth Potential Ahead?

Gland Pharma, Caplin Point, Nephrocare: These 3 Pharma Stocks See Strong Growth Potential Ahead?

by Sakshi Batra |Sep 2, 2026

Three pharma stocks are in focus after a series of positive regulatory and international developments. Business Today’s Neetu Chandra Sharma explains why Gland Pharma, Caplin Point and Nephrocare Heal...